Role of Magnesium in anaesthesia

Reading File

Finding Sources

Searching PubMed

"magnesium" AND "anaesthesia" AND "perioperative"

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have sufficient material to write a comprehensive answer. Let me compile all the information gathered from Miller's Anesthesia, Barash, Morgan & Mikhail, and PubMed.

Role of Magnesium in Anaesthesia

Magnesium (Mg²⁺) is a physiologically versatile agent with a well-established and expanding role in perioperative care. It acts through multiple mechanisms and is used across anaesthetic subspecialties.

Pharmacology and Mechanism of Action

Magnesium exerts its effects through several key pathways:

NMDA receptor antagonism - Mg²⁺ is a physiological voltage-dependent blocker of the NMDA (N-methyl-D-aspartate) receptor channel. It binds at a site different from ketamine on the receptor, blocking calcium influx. This underpins its analgesic, anticonvulsant, and anti-hyperalgesic effects.
Calcium channel antagonism - Magnesium competes with calcium at voltage-gated calcium channels, inhibiting calcium entry at presynaptic nerve terminals. This reduces acetylcholine release at the neuromuscular junction.
Membrane stabilisation - It decreases the excitability of muscle fiber membranes by attenuating postjunctional potentials.
Catecholamine modulation - Magnesium blunts catecholamine release from the adrenal medulla and sympathetic nerve terminals, contributing to cardiovascular stability.

Clinical Uses in Anaesthesia

1. Obstetric Anaesthesia - Preeclampsia and Eclampsia

This is the most established use. Magnesium sulfate (MgSO₄) is the agent of choice for:

Seizure prophylaxis in preeclampsia - the Magpie Trial showed a 50% reduction in eclamptic seizures (0.8% vs 1.6%) in over 10,000 women
Treatment of eclampsia - superior to phenytoin and benzodiazepines for seizure control

Standard regimen: Loading dose 4 g IV over 15-20 minutes, followed by maintenance infusion of 1-2 g/hr.

From an anaesthetic standpoint, ongoing magnesium sulfate therapy profoundly affects anaesthetic management (see NMB interactions below). - Miller's Anesthesia, 10e

2. Potentiation of Neuromuscular Blockade (NMB)

This is one of the most important perioperative drug interactions. MgSO₄ potentiates nondepolarizing NMBDs through:

Prejunctional: inhibits Ca²⁺-triggered acetylcholine release
Postjunctional: reduces muscle membrane excitability

After 40 mg/kg MgSO₄:

ED₅₀ of vecuronium is reduced by 25%
Onset time is nearly halved
Recovery time is nearly doubled
Neostigmine-induced reversal is also attenuated

Key clinical implications:

Reduce NMB doses in patients on magnesium
Use objective neuromuscular monitoring (TOF) - subjective assessment is unreliable
Prolonged weakness can occur with succinylcholine if prior magnesium therapy has reduced pseudocholinesterase activity or exacerbated block
Sugammadex reversal remains effective - Miller's Anesthesia, 10e

3. Multimodal Analgesia - NMDA Receptor Antagonism

Magnesium is increasingly used as a component of multimodal analgesia:

Suppresses neuropathic pain
Potentiates morphine analgesia
Attenuates opioid tolerance (morphine tolerance)
Abolishes central sensitisation and development of hyperalgesia
Reduces postoperative opioid consumption

Because magnesium and ketamine bind to different sites on the NMDA receptor, their combination may produce a "superadditive" analgesic effect. Optimal perioperative dosing is still being established; side effects include hypotension and NMB potentiation. - Barash Clinical Anaesthesia, 9e; Morgan & Mikhail, 7e

Intrathecal magnesium has also been shown to prolong neuraxial fentanyl analgesia. - Miller's Anesthesia, 10e (References)

4. Antiarrhythmic Effects

Magnesium has class IV-like antiarrhythmic properties. Key indications:

Torsades de pointes (TdP): IV magnesium sulfate is first-line treatment, effective even without shortening the QT interval - Braunwald's Heart Disease
Intraoperative ventricular arrhythmias in the context of hypomagnesaemia
Supraventricular tachycardias
Management of digoxin toxicity-related arrhythmias

Hypomagnesaemia itself can precipitate PACs, atrial fibrillation, ventricular tachycardia, TdP, and VF. - Tietz Laboratory Medicine; Katzung Pharmacology

5. Attenuation of Haemodynamic Response to Laryngoscopy

Intravenous magnesium sulfate, given pre-induction, blunts the catecholamine-mediated pressor response to laryngoscopy and intubation. This is particularly useful in:

Hypertensive patients
Patients with ischaemic heart disease
Patients at risk from acute cardiovascular stress

6. Tocolysis

Magnesium sulfate relaxes uterine smooth muscle and is used as a tocolytic agent for preterm labour. However, it is less favoured now than calcium channel blockers due to side-effect profile, and is primarily used for neuroprotection of the premature neonate (reduces cerebral palsy risk).

7. Bronchospasm

IV and nebulised magnesium sulfate can be used as adjunct therapy in severe acute asthma/bronchospasm, particularly when refractory to initial bronchodilators. The mechanism involves smooth muscle relaxation via calcium antagonism. The 2024 systematic review (PMID 39089452) also identified a role in preventing laryngospasm in paediatric general anaesthesia.

8. Neuroprotection

Magnesium has demonstrated neuroprotective properties in animal models via NMDA blockade (reducing excitotoxicity). Its role in:

Premature neonates: maternal MgSO₄ before preterm delivery reduces the risk of cerebral palsy
Clinical trials in traumatic brain injury and stroke - have not shown consistent benefit in humans

9. Prevention of Shivering

Postanaesthetic and perioperative shivering can be suppressed by IV magnesium, attributed to its thermoregulatory and NMDA-blocking properties, though it is not a first-line agent (meperidine/pethidine remains the standard).

Monitoring Magnesium Therapy

Serum magnesium levels and clinical signs guide therapy:

Serum Mg²⁺ (mEq/L)	Clinical Effect
1.5-2.0 (normal)	Normal physiology
4-8	Therapeutic anticonvulsant range
5-10	Loss of deep tendon reflexes (first sign of toxicity)
10-13	Respiratory paralysis
>15	Cardiac arrest

Clinical monitoring: Deep tendon reflexes (patellar reflex) serve as the bedside monitor - loss indicates impending toxicity. Urine output must be maintained (>25-30 mL/hr) as the kidneys are the primary excretory route.

Antidote: Calcium gluconate 1 g IV (or calcium chloride) reverses magnesium toxicity.

Pharmacokinetics

Distribution: mainly intracellular; normal plasma level 1.5-2.5 mEq/L
Excretion: almost entirely renal - reduce dose in renal impairment
No hepatic metabolism
Crosses the placenta freely (therapeutic fetal levels achieved)

Contraindications and Cautions

Myasthenia gravis - severe exacerbation of neuromuscular weakness
Renal failure - accumulation; dose reduction and close monitoring required
Concurrent use with calcium channel blockers (theoretical risk of enhanced hypotension and NMB, though large retrospective data suggest it is manageable)
Heart block - may worsen conduction

Summary Table

Role	Mechanism	Setting
Preeclampsia/eclampsia seizure prophylaxis	NMDA + membrane stabilisation	Obstetric anaesthesia
Potentiates nondepolarizing NMB	Inhibits ACh release + reduces membrane excitability	All GA cases in patients on MgSO₄
Multimodal analgesia	NMDA receptor antagonism	Perioperative pain management
Antiarrhythmic (TdP)	Calcium channel blockade	Cardiac emergencies, ICU
Blunts intubation pressor response	Catecholamine suppression	Induction of anaesthesia
Bronchospasm/laryngospasm	Smooth muscle relaxation	Airway emergencies
Tocolysis / neuroprotection	Smooth muscle relaxation + NMDA blockade	Obstetrics
Shivering prevention	Thermoregulatory + NMDA	PACU

Recent evidence: A 2024 systematic review and meta-analysis (PMID 39089452) confirmed the efficacy of MgSO₄ in preventing laryngospasm in paediatric patients undergoing general anaesthesia. A 2024 network meta-analysis (PMID 39366846) assessed magnesium among non-opioid analgesic adjuvants in multimodal analgesia for reducing postoperative opioid consumption, particularly in obese patients.

Sources: Miller's Anesthesia 10e | Barash Clinical Anaesthesia 9e | Morgan & Mikhail Clinical Anesthesiology 7e | Braunwald's Heart Disease | Katzung Pharmacology 16e

This is a shared conversation. Sign in to Orris to start your own chat.